Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, age: between 18 and 50 years~2. Defect: isolated ICRS grade III or IV single defect chondral lesions on femoral condyles~3. Defect size: 1 to \< 4 cm2 after debridement to healthy cartilage up to 6 mm in depth.Assessment with MRI at screening and per estimation during arthroscopy prior to randomization~4. Nearly intact chondral structure surrounding the defect as well as an intact corresponding joint area~5. Informed consent signed and dated by patient~6. Patient understands the strict rehabilitation protocol and follow-up programme and is willing to follow it~7. In case of pain, patient agrees to use only paracetamol mono- (max 4 g/day) or combination preparation and oral and/or topic NSAIDs during the trial and to discontinue the use of oral and/or topic NSAIDs and/or paracetamol combination preparation 1 week before each visit whereas the use of paracetamol monopreparation (max 4 g/day) is allowed. However, in the morning of the visit day, no pain medication is allowed. Other pain medications are allowed during surgical procedure and may be taken for a period not exceeding 4 weeks after surgery.~Exclusion Criteria:~1. Defects on both knees at the same time~2. Radiological signs of osteoarthritis~3. Osteochondritis dissecans (OCD)~4. Any signs of knee instability~5. Valgus or varus malalignment (more than 5° over the mechanical axis)~6. Clinically relevant second cartilage lesion on the same knee~7. More than 50 % resection of a meniscus in the affected knee or incomplete meniscal rim~8. Rheumatoid arthritis, parainfectious or infectious arthritis, and condition after these diseases~9. Pregnancy and planned pregnancy (no MRI possible)~10. Obesity (Body Mass Index \>30)~11. Uncontrolled diabetes mellitus~12. Serious illness~13. Poor general health as judged by physician~14. Participation in concurrent clinical trials or previous trials within 3 months of screening~15. Previous treatment with ACT in the affected knee~16. Microfracture performed less than 1 year before screening in the affected knee~17. Alcohol or drug (medication) abuse~18. Meniscal transplant in the affected knee~19. Meniscal suture (in the affected knee) three months prior to baseline~20. Mosaicplasty (Osteoarticular Transplant System, OATS) in the affected knee~21. Having received hyaluronic acid intra-articular injections in the affected knee within the last 3 months before baseline~22. Taking specific osteoarthritis drugs such as chondroïtin sulfate, diacerein, nglucosamine,piascledine, capsaicin within 2 weeks before baseline~23. Corticosteroid treatment by systemic or intraarticular route within the last month of baseline or intramuscular or oral corticosteroïds within the last 2 weeks before baseline~24. Chronic use of anticoagulants~25. Any concomitant painful or disabling disease of the spine, hips or lower limbs that would interfere with evaluation of the afflicted knee~26. Any clinically significant or symptomatic vascular or neurological disorder of the lower extremities~27. Any evidence of the following diseases in the affected knee: septic arthritis, inflammatory joint disease, recurrent episodes of pseudogout, Paget's disease of bone, ochronosis, acromegaly, haemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders, collagen gene mutation~28. Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1,-2) and/or hepatitis C virus (HCV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- co.don chondrosphere® (Type: EXPERIMENTAL): co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
- Micofracture (Type: ACTIVE_COMPARATOR): A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).